Leadership and Structure
Amylin is prepared to execute on an extraordinary opportunity in 2012, with a focus on the following value-driving opportunities:
- Successfully launch BYDUREON™ (exenatide extended-release for injectable suspension) in the United States (U.S.)
- Secure a partner outside the U.S. for exenatide
- Maximize the value of BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection
- Advance the metreleptin and exenatide suspension development programs
- Continue focused financial discipline